Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMGX3MK)

Drug Name
L-655240 Drug Info
Synonyms
L-655,240; 103253-15-2; L-655240; L 655240; CHEMBL362223; 3-[1-(4-Chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]-2,2-dimethyl propanoic acid; 1-((4-chlorophenyl)methyl)-5-fluoro-a,a-3-trimethyl-(1h)-indole-2-propanoic acid; SR-01000075967; JLPYLHLUHJOPNL-UHFFFAOYSA-N; Tocris-1698; Lopac-L-9539; AC1L3TX4; Lopac0_000670; SCHEMBL3252820; CHEBI:93563; CTK8E8278; MolPort-003-958-591; HMS3268O17; ZINC2526554; BDBM50168772; AKOS024456751; CCG-204756; 3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid
Cross-matching ID
PubChem CID
122070
ChEBI ID
CHEMBL362223
CAS Number
CAS 103253-15-2
TTD Drug ID
D0I9JH

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.14 0.00e+0 34/36 (94.44%) MCM6;POLE2;PRIM2;...
Ribosome biogenesis in eukaryotes 1.89 9.13e-3 52/108 (48.15%) REXO2;NMD3;POP7;...
Spliceosome 1.76 2.84e-2 101/150 (67.33%) PRPF4;HSPA8;PRPF8;...
Other glycan degradation -1.65 4.84e-2 13/18 (72.22%) GLB1;AGA;MAN2C1;...
Endometrial cancer -1.66 4.74e-2 56/58 (96.55%) GSK3B;GADD45B;AKT3;...
beta-Alanine metabolism -1.67 4.56e-2 25/30 (83.33%) ALDH2;ECHS1;EHHADH;...
Histidine metabolism -1.70 3.59e-2 16/22 (72.73%) ALDH3A1;HNMT;ALDH2;...
Nicotine addiction -1.70 3.78e-2 32/40 (80%) GABRB3;GABRP;GABRA1;...
Fructose and mannose metabolism -1.70 3.68e-2 30/33 (90.91%) FBP1;GMPPA;ALDOA;...
Galactose metabolism -1.73 2.99e-2 26/31 (83.87%) G6PC3;AKR1B1;GAA;...
Antigen processing and presentation -1.74 2.73e-2 60/78 (76.92%) B2M;CTSB;HSP90AA1;...
Mineral absorption -1.77 2.07e-2 48/60 (80%) MT1E;SLC26A3;FTL;...
Graft-versus-host disease -1.81 1.51e-2 32/42 (76.19%) CD80;HLA-C;CD86;...
Arginine and proline metabolism -1.83 1.19e-2 39/50 (78%) ALDH2;MAOB;P4HA2;...
PPAR signaling pathway -1.84 1.06e-2 66/74 (89.19%) HMGCS1;PLIN2;CPT2;...
Ferroptosis -1.86 5.13e-3 36/41 (87.8%) MAP1LC3B;ACSL4;HMOX1;...
Pentose phosphate pathway -1.90 2.82e-3 25/30 (83.33%) FBP1;G6PD;ALDOA;...
Lysosome -1.90 3.13e-3 115/128 (89.84%) CTSL;PPT1;GNS;...
Allograft rejection -1.93 1.76e-3 32/38 (84.21%) CD80;HLA-C;CD86;...
Autoimmune thyroid disease -1.94 2.01e-3 46/53 (86.79%) CD80;HLA-C;CD86;...
Tyrosine metabolism -1.95 2.35e-3 30/36 (83.33%) ADH6;ALDH3A1;PNMT;...
Metabolism of xenobiotics by cytochrome P450 -1.97 2.82e-3 49/77 (63.64%) UGT2B4;GSTA3;GSTT2;...
Pentose and glucuronate interconversions -1.97 3.52e-3 17/34 (50%) UGT2B4;AKR1B1;KL;...
Type I diabetes mellitus -1.98 4.70e-3 38/43 (88.37%) CD80;HLA-C;CD86;...
Phenylalanine metabolism -2.04 0.00e+0 14/17 (82.35%) ALDH3A1;GLYAT;MAOB;...
Cholesterol metabolism -2.15 0.00e+0 44/50 (88%) STARD3;LCAT;LRPAP1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H